Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Open-Label, Phase II Trial of Atezolizumab Plus Bevacizumab Alone or Combined with External Beam RadioTherapy for HepatoCellular Carcinoma with Macrovascular Invasion (ALERT-HCC)

NCT05992220 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT05992220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05992220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Open-Label, Phase II Trial of Atezolizumab Plus Bevacizumab Alone or Combined with External Beam RadioTherapy for HepatoCellular Carcinoma with Macrovascular Invasion (ALERT-HCC)
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
October 22, 2022
Completion date
March 31, 2026
Enrollment
138 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular cancer, hepatocellular carcinoma, hepatocellular carcinoma non-resectable, hepatocellular carcinoma stage iv, liver cancer